TrialJournal of neurology, neurosurgery, and psychiatry2012

Posiphen as a candidate drug to lower CSF amyloid precursor protein, amyloid-β peptide and τ levels: target engagement, tolerability and pharmacokinetics in humans.

Maria L Maccecchini et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.